Forum: BioPharma » NASH - bedrijven

Wil Helmus 18 april 2019 21:09

www.google.com/amp/s/seekingalpha.com...

Wil Helmus 25 april 2019 12:28

Shire’s fast-track NASH drug abruptly stopped in phase 2

www.fiercebiotech.com/biotech/shire-s...

Wil Helmus 25 april 2019 14:53

Press Releases

April 25, 2019

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 25, 2019-- Gilead Sciences, Inc.(Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), for patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis (NASH), did not meet the pre-specified week 48 primary endpoint of a = 1-stage histologic improvement in fibrosis without worsening of NASH.

In the study of 802 enrolled and dosed patients, 9.3 percent of patients treated with selonsertib 18 mg (p=0.42 versus placebo) and 12.1 percent of patients treated with selonsertib 6 mg (p=0.93) achieved a = 1-stage improvement in fibrosis according to the NASH Clinical Research Network (CRN) classification without worsening of NASH after 48 weeks of treatment, versus 13.2 percent with placebo. Selonsertib was generally well tolerated and safety results were consistent with prior studies.

“While we had hoped for different outcomes from the STELLAR program, we remain focused and committed to developing highly effective treatments for patients living with advanced fibrosis due to NASH. We are actively exploring the STELLAR data and will work with external collaborators like PathAI and insitro, to further our understanding of this complex disease and advance our development programs. We thank the patients and their physicians who participated in the STELLAR program for contributing to these efforts,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “We believe that effective therapy for NASH will ultimately require a combination approach that targets distinct pathways involved in the pathogenesis of this disease. In this regard, we look forward to data from the Phase 2 ATLAS combination trial of selonsertib, cilofexor and firsocostat in patients with advanced fibrosis due to NASH, which will be available later this year.”

Gilead will now work with the Data Monitoring Committee and investigators to conclude the STELLAR-3 study in a manner consistent with the best interests of each patient.

Selonsertib, cilofexor, and firsocostat, alone or in combination, are investigational compounds and are not approved by the U.S. Food & Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established for these agents.

Lingus 11 juni 2019 16:07

De bodem uit Genfit: seekingalpha.com/news/3470433-cymabay...
Op tijd uitgestapt...

Noob nr1 18 juni 2020 06:36

pharmaphorum.com/news/analyst-tip-inv...

AEX	884,07	0,00%
EUR/USD	1,0613	-0,12%
FTSE 100	7.965,53	-0,38%
Germany40^	17.893,90	-0,74%
Gold spot	2.384,55	+0,06%
NY-Nasdaq Composite	15.885,02	-1,79%

AALBER...	0,00 0,00% 0 0
ABN AM...	0,00 0,00% 0 0
Accsys	0,00 0,00% 0 0
ACOMO	0,00 0,00% 0 0
ADYEN NV	0,00 0,00% 0 0

AALBER...	0,00 0,00% 0 0
ABN AM...	0,00 0,00% 0 0
Accsys	0,00 0,00% 0 0
ACOMO	0,00 0,00% 0 0
ADYEN NV	0,00 0,00% 0 0

BioPharma« Terug naar discussie overzicht

NASH - bedrijven

Meedoen aan de discussie?

Direct naar Forum

Indices

Stijgers

Dalers

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links